Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Dec 01, 2022

Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy

- First global regulatory approval for treatment of this rare genetic disease - SOUTH PLAINFIELD, N.J. , Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency , ANVISA (Agência Nacional de Vigilância Sanitária), has approved

Nov 17, 2022

Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA

- Upstaza ™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency - - MHRA authorization follows recent European Union authorization - - AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability - SOUTH PLAINFIELD,

Oct 27, 2022

PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results

- Total quarterly revenue of $217 million , representing 57% year-over-year growth - - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing with Blackstone with up to $1 billion of low-cost, low-dilution capital - - Pipeline of multiple innovative

Oct 27, 2022

PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding

- Blackstone investment accelerates innovative product pipeline - - PTC will leverage Blackstone's network and life sciences expertise to broaden business development effort - - PTC to receive $350 million in cash at close - SOUTH PLAINFIELD, N.J. and NEW YORK , Oct.

Oct 18, 2022

PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

SOUTH PLAINFIELD, N.J. , Oct. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington's disease at study sites globally.

Oct 13, 2022

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results

SOUTH PLAINFIELD, N.J. , Oct. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022 financial results and provide an update on the company's business and outlook on Thursday, Oct.

Oct 11, 2022

PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society

- Presentations include age of loss of ambulation and preservation of upper limb function following treatment with Translarna in patients with nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Oct. 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc.

Sep 07, 2022

PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community

- 2022 recipients include patient advocacy organizations from Brazil , Greece , Turkey , and the U.K. - SOUTH PLAINFIELD, N.J. , Sept. 7, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy.

Sep 01, 2022

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J. , Sept. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Wells Fargo 17 th Annual Healthcare Conference Thursday, Sept. 8 , at 1:55 p.m.

Aug 04, 2022

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results

- Total revenue of $166 million , representing 42% year-over-year growth – - Upstaza™ gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first commercial patient treated – SOUTH PLAINFIELD, N.J. , Aug.

Pagination

First page
Previous page
…
Page 4
Page 5
Current page 6
Page 7
Page 8
…
Next page
Last page